Sir,
Hydroxychloroquine (HCQ) has been widely prescribed by Rheumatologists since the 1950s. Retinal toxicity, particularly with treatment duration >5 years, is a recognised complication. The British Society for Rheumatology (BSR) recently updated its screening guidelines:1
‘Patients should have baseline formal ophthalmic examination, ideally including objective retinal assessment for example using optical coherence tomography (OCT), within 1 year of commencing HCQ……
(and) annual eye assessment (ideally including optical coherence tomography) if continued for >5 years’
This reflected availability of data from OCT, and recognition that risk of HCQ-induced retinal toxicity is greater than previously thought. We set out to quantify HCQ use in England and Wales, to understand the impact of the new guidelines on ophthalmology services.
Estimate of new starters/year
Data from the Healthcare Quality Improvement Partnership (HQIP) Early Inflammatory Arthritis national audit and The Early Rheumatoid Arthritis Network (ERAN) were reviewed. ERAN (2001–2011) reported HCQ use of 22%. HQIP (2014–2016) reported 51.7% of patients newly diagnosed with rheumatoid arthritis (RA) were commenced on HCQ. The higher reported usage in HQIP may reflect a movement towards combination therapy in contemporary practice.
The Systemic Lupus International Collaborating Clinics Inception Cohort reported 67% of SLE patients commence HCQ in the first year.2
Extrapolating using UK disease incidence data for RA and Lupus,3, 4 and an adult population of 47 300 000, this equates to around 11 000 new HCQ initiations per year in England and Wales.
Individuals that are established on HCQ
Considerable effort is needed to bring established patients in line with the new guidelines. NHS Digital provides summary data from England on community expenditure and prescribing.5 In 2016, 58 810 415 HCQ 200 mg tablets were dispensed, equating to 161 124 prevalent users (assuming 200 mg daily dose).
Horizon scanning and time trends
Within rheumatology, treatment guidelines have substantially evolved in the last decade, with recommendations for intensive therapy advocating targets of disease remission. Strategy trials have demonstrated cost benefits to combination therapy.
NHS Digital provides a useful data source for examining the time trends of HCQ use (Figure 1).
Implications
Retinal assessment based on the new BSR guidance will significantly increase pressure on NHS resources. This will include a transient catch up period for established HCQ users requiring additional screening, as well as an increased burden for new starters. This brings the cost-benefit of HCQ into question.
The Royal College of Ophthalmologists (RCOphth) is undertaking an independent review of the evidence, and new guidelines with collaborative recommendations are imminent.
References
Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford, England) 2017; 56 (6): 865–868.
Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae S-C et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2015; 74 (8): 1530–1536.
Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP . The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013; 72 (8): 1315–1320.
Johnson AE, Gordon C, Palmer RG, Bacon PA . The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995; 38 (4): 551–558.
Content.digital.nhs.uk. (2017). Find data - NHS Digital. [online] Available at: http://content.digital.nhs.uk/searchcatalogue?productid=24706&q=+title%3a%22prescription+cost+analysis%22&sort=Relevance&size=10&page=1#top (Accessed 1 June 2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Mark Yates is funded by the BSR. James Galloway is on the RCOphth hydroxychloroquine guidelines committee. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yates, M., Malaiya, R., Stack, J. et al. Hydroxychloroquine use: the potential impact of new ocular screening guidelines. Eye 32, 161–162 (2018). https://doi.org/10.1038/eye.2017.166
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2017.166
This article is cited by
-
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom
Eye (2023)
-
Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria
Eye (2021)
-
The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary
Eye (2018)